Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference By: ACCESSWIRE January 07, 2024 at 21:20 PM EST PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions. A live webcast of the presentation can be accessed on the Investors section of MorphoSys' website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company's website following the presentation. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer . As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn. For more information, please contact: Media Contacts: Thomas BiegiSenior Vice President, Corporate AffairsTel: +49 (0)151 / 74612318thomas.biegi@morphosys.com Investor Contact: Dr. Julia NeugebauerVice President, Global Investor RelationsTel: +49 (0)89 / 899 27 179julia.neugebauer@morphosys.com Eamonn NolanDirector, Corporate Communications & Investor RelationsTel: +1 617-548-9271eamonn.nolan@morphosys.com SOURCE: MorphoSys AG View the original press release on accesswire.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference By: ACCESSWIRE January 07, 2024 at 21:20 PM EST PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions. A live webcast of the presentation can be accessed on the Investors section of MorphoSys' website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company's website following the presentation. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer . As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn. For more information, please contact: Media Contacts: Thomas BiegiSenior Vice President, Corporate AffairsTel: +49 (0)151 / 74612318thomas.biegi@morphosys.com Investor Contact: Dr. Julia NeugebauerVice President, Global Investor RelationsTel: +49 (0)89 / 899 27 179julia.neugebauer@morphosys.com Eamonn NolanDirector, Corporate Communications & Investor RelationsTel: +1 617-548-9271eamonn.nolan@morphosys.com SOURCE: MorphoSys AG View the original press release on accesswire.com
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company's Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions. A live webcast of the presentation can be accessed on the Investors section of MorphoSys' website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company's website following the presentation. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer . As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn. For more information, please contact: Media Contacts: Thomas BiegiSenior Vice President, Corporate AffairsTel: +49 (0)151 / 74612318thomas.biegi@morphosys.com Investor Contact: Dr. Julia NeugebauerVice President, Global Investor RelationsTel: +49 (0)89 / 899 27 179julia.neugebauer@morphosys.com Eamonn NolanDirector, Corporate Communications & Investor RelationsTel: +1 617-548-9271eamonn.nolan@morphosys.com SOURCE: MorphoSys AG View the original press release on accesswire.com
